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Abstract: The human population continues to grow and is estimated to rise to 10.1   billion 
by the end of the century. Therefore, there is still an unmet need for safe and highly effective 
contraceptive options for both men and women. Current options available to men include 
withdrawal, condoms, and vasectomy. Methods in development fall into two categories: 
hormonal and nonhormonal. This review will provide an overview of the testosterone 
combinations and immunocontraception of hormonal targets. Nonhormonal immunocontra-
ception of sperm proteins will also be examined, together with the use of agents to disrupt 
other sperm-associated targets and pathways. The categories focused on include epididymal 
proteins, testicular kinases, epigenetic reader proteins, opioids, lonidamine derivatives, 
retinoic acid, microRNAs associated with spermatogenesis, and plant extracts.   Considering 
these developments, the number of options available to men is likely to increase in the near 
future.
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Introduction
Despite the number of contraceptive methods available, unintended pregnancies 
still occur worldwide. This is in part due to a lack of appreciation of the unin-
tended pregnancy risk, particularly among teenagers in developed countries where 
contraception is readily available. However, there is still a worldwide unmet need 
for more affordable, effective, and practical contraceptives, indicating that further 
technological advancements or innovations to existing products are required.1 The 
oral contraceptive pill for women has had significant impact on societal dynamics 
and socioeconomic benefits, while the development of male contraceptive options 
equivalent to female products has proven an elusive goal.2 The main reason for 
this is that while sperm production can be controlled by the administration of sex 
steroids, there is also a decrease in testosterone that requires “add-back” therapy.3 
Nevertheless, while the human population continues to rise – from 7 billion people 
in 2011 to an estimated 10.1 billion by the end of the century4 – there is still an 
unmet need for safe and highly effective contraceptive options for both men and 
women. Further, expansion of available products allows both partners to share 
family planning responsibility. Better contraceptive availability and use also has an 
impact on reducing maternal deaths through preventing high-risk pregnancies and 
unsafe abortions.5 This review focuses on emerging options in male contraception 
and looks at potential future directions.
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Male contraceptive options
Current options available to men include withdrawal (coitus 
interruptus), condoms – categorized as behavioral and bar-
rier methods, respectively – and vasectomy.6 While the 
withdrawal method is considered unreliable, condom use has 
increased due to recognition of a need for protection against 
sexually transmitted infections and few adverse side effects. 
Current condom developments include the use of newer poly-
urethane materials, which are thinner, stronger, and less aller-
genic, and the inclusion of more effective spermicides.7 In 
contrast, vasectomy is considered a safe and simple method, 
but the drawback is that it is not reliably reversible and there 
is still a ,1% chance of unwanted pregnancy.8
In recent years, a growing number of new methods have 
emerged, such as reversible inhibition of sperm under guid-
ance (RISUG), or “Vasalgel”, as an alternative to vasectomy, 
most of which are still under development. RISUG is in Phase 
III clinical trials in India and is now also being investigated 
in the USA. RISUG involves the injection of a polymer into 
the vas deferens, rather than severing or clamping it, as in 
vasectomy. The polymer coats the inside walls of the vas 
deferens and solidifies and anchors itself to the microscopic 
folds of the inner walls of the vas deferens. As sperm come 
into contact with the polymer, the combination of positive and 
negative charges on the polymer damage the sperm, render-
ing them immotile.9 It is proposed that the polymer can be 
removed from the vas deferens, thereby restoring fertility.
Apart from mechanical methods, which have seen few 
emerging options, new technologies generally fall into two 
categories: hormonal and nonhormonal. The requirements 
for the ideal male contraceptive include that it:
•	 Be acceptable to both partners.
•	 Be effective (preferably without a lag period).
•	 Can be applied independently of the sexual act.
•	 Should not interfere with libido or sexual activity.
•	 Not have unacceptable side effects (long or short).
•	 Be fully reversible without impact on subsequent 
offspring.
•	 Have equivalent effectiveness to female methods.
A summary of emerging male contraceptive options is 
given in Table 1.
Male hormonal contraceptives
Male hormonal contraceptive methods are based on the sup-
pression of luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH) to decrease testosterone levels. In particular, 
intratesticular testosterone has to be drastically curtailed to 
effectively disrupt spermatogenesis.10 However, circulating 
testosterone has to be maintained at a particular level to 
retain androgenicity and this is usually achieved by add-
back therapy.
Testosterone-based therapies have been developed to 
suppress LH and FSH. Historically, these have included 
testosterone enanthate (200 mg administered by weekly 
intramuscular injection)11 and testosterone undecanoate 
(1000 mg administered every 4 weeks by depot injection – 
this is now sold as Nebido® (Bayer Healthcare, Monheim, 
Germany) for treating hypogonadism).8 However, since 
testosterone-only therapies do not achieve azoospermia in 
all ethnicities (eg, lower response in Caucasians compared 
with total azoospermia achieved in East Asian men), other 
fertility disrupting agents are also required with longer last-
ing effects.12 Developments included testosterone plus depot 
medroxyprogesterone acetate (administered at 3-weekly 
intervals),13 testosterone plus 19-norethisterone enanthate 
(administered 8-weekly by injection),14 and testosterone 
plus etonogestrel (injection and implant).15 However, the 
organizations/firms that initiated this research subsequently 
abandoned these male contraception programs and the work 
on them ceased. More recently, combinations of testosterone 
with gonadotropin-releasing hormone (GnRH) analogs and 
newer progestogens such as nestorone have been examined. 
However, the costs of manufacture and need for daily or 
weekly administration of the GnRH preparations proved 
prohibitive for further research to be pursued.12 In contrast, 
daily use of testosterone/nestorone gel formulations has been 
shown to suppress sperm levels to #1 million sperm/mL in 
89% of men, with few adverse effects.16 Nieschlag12 has com-
prehensively summarized the advantages and disadvantages 
of the various testosterone and testosterone combination 
formulations.
A potential androgen for the future, which may enable 
single-agent development, is dimethandrolone undeconoate 
(DMAU). This androgen binds to progesterone receptors 
and can be administered orally or by injection17 but has yet 
to be tested clinically.
Immunocontraception of hormonal targets
Contraceptive vaccines (immunocontraception) against vari-
ous hormonal targets have been investigated over the last two 
decades. The most successful of these is currently used to 
control animal fertility and is based on the neutralization of 
GnRH (GonaCon™, United States Department of Agricul-
ture, PA, USA).18–20 Figure 1 shows how immunoneutraliza-
tion of GnRH affects synthesis of LH and FSH, which in 
turn affects testosterone production and spermatogenesis. 
A recent review examined other hormonal targets for male 
immunocontraception, including immunization against LH 
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and FSH, but this work on these gonadotrophins is no longer 
being investigated clinically for contraception.21
Risks and benefits associated with hormonal 
contraceptives
Achieving acceptable levels of oligospermia or, if possible, 
azoospermia, requires intratesticular serum testosterone 
levels to drop to the hypogonadal range (typically below 
350 ng/dL)8 – this potentially increases the risk of loss of 
androgenicity, affecting the male sexual organs and char-
acteristics, bone structure, and libido, as well as resulting 
in negative psychotropic effects.10 This can be improved by 
targeting intratesticular testosterone using a dual-action con-
traceptive – that is, combining the addition of testosterone 
with substances that suppress the secretion of LH or FSH 
(or both), while replacing systemic testosterone by combin-
ing the contraceptive with an androgen. It is believed that 
by doing so the vast majority of hormonal contraceptives 
can maintain a high level of efficacy with minimal side 
effects, although most have not focused on the side effects.22 
The most common of which include acne, suppression of 
high-density lipoprotein cholesterol, and a slight increase 
in hematocrit (due to suppression of hepcidin), all of which 
can be satisfactorily monitored.23 Other side effects – such 
as night sweats and decrease in testis volume – are reversible 
and, although commonly experienced, raise little concern and 
Table 1 Emerging contraceptive targets
Contraceptive Mechanism Target Commercial 
possibility
Reversible Reference
Barrier and vasectomy
Condom Sperm barrier Sperm containment Yes Yes Qureshi and 
Attaran7
Reversible inhibition of  
sperm under guidance
Vasectomy Sperm motility Yes Yes Chaudhury 
et al9
Hormonal
Testosterone Inhibiting gonadotropin  
production
Spermatogenesis  
and testosterone
Possibly Yes, though may  
depend on length  
of time administered
Nieschlag10 
Nieschlag  
et al78
Testosterone  
combinations
Inhibiting gonadotropin  
(LH, FSH) production
Spermatogenesis  
and testosterone
Possibly Depends on length  
of time administered
Nieschlag10
Immunocontraceptives Inhibiting gonadotropin- 
releasing hormone and  
gonadotropins (LH, FSH)
Spermatogenesis  
and testosterone
Possibly Depends on  
length of time  
administered
Ferro and 
Garside21
Nonhormonal
Sperm protein vaccines Inhibiting sperm function Sperm motility,  
sperm–egg binding
Yes: depends on  
vaccine development
Yes Naz32
Epididymal proteins Inhibiting sperm function Sperm motility,  
sperm–egg binding
Possibly: EPPIN,  
SEMG1
Unknown Silva et al41 
Robert and 
Gagnon42
Testicular kinases Spermatogenesis and  
fertilization
Disrupt sperm  
production and  
fertilization
Unknown Unknown Xu et al47
Blood-testis boundary Spermatogenesis Disrupt sperm  
production
Unknown Unknown Mital et al34
Opioids Hormone production,  
sperm function
Act at several levels  
of sperm production  
and function
Unknown Unknown Subiran  
et al52
Lonidamine derivatives Spermatogenesis Prevent release of  
sperm from Sertoli cells
Unknown Unknown Cheng  
et al54
Retinoic acid Spermatogenesis Disrupt sperm  
production
Unknown Unknown Brooks and 
van der 
Horst58
miRNAs Spermatogenesis Disrupt sperm  
production
Research stage  
too early
Unknown Papaioannou 
and Nef60
Plant extracts Spermatogenesis Disrupt sperm  
production
Unknown: most  
have shown toxicity
Unknown Ogbuewu  
et al66
Heat treatment Spermatogenesis Disrupt sperm  
production
Possibly Yes: for short- 
term application
Setchell69
Abbreviations: miRNA, microribonucleic acid; LH, luteinizing hormone; FSH, follicle stimulating hormone; EPPIN, epididymal protease inhibitor; SEMG1, semenogelin 1.
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are unlikely to result in discontinuation of the treatment.24 
However, as with a large number of hormonal treatments, 
there is a risk of psychotropic effects, including irritability, 
anxiety, depression, and an increase in emotionally fragile 
states – these psychotropic effects can be severe enough 
to result in the subject withdrawing from the treatment 
program.25
Of course, the side effects vary depending on the con-
traceptive used and the administration route. Apart from the 
increase in testosterone levels causing acne, general skin 
irritation and tenderness is frequently found at the site of 
injection, patch application, or transdermal preparations.25 
For hypogonadal men, there is a further risk of gynecomastia 
(development of larger than normal mammary glands in 
males).
It should be noted that targeting LH and FSH decreases 
sperm production but does not affect sperm that have already 
been produced; therefore, other contraceptive methods must 
be used until existing sperm have reached maturity and exited 
the testicles – this typically takes 2–3 months.26 There is also 
a delay in return to the male’s natural sperm count after dis-
continuing the treatment26 – in the case of testosterone plus 
depot medroxyprogesterone acetate, this delay can last several 
months.10 Overall, however, the high efficacy of hormonal 
contraceptives outweigh the small concerns of side effects. 
It should also be noted that early concerns about an increase 
in cardiovascular disease or prostate cancer risk have so far 
been unfounded.25
Male nonhormonal contraceptives
Research into nonhormonal methods of male contracep-
tion are numerous and the focus of this section is on novel 
technologies that are at various stages of development and/
or in clinical trial, thus may be the male contraceptives of 
the future. Three significant areas of development include 
(1) the immunization (active or passive) of males with 
antigens/antibodies that can block sperm function; (2) the 
administration of site-directed compounds to block spermato-
genesis or specific sperm function(s) necessary for normal 
fertilization; and (3) the administration of herbal extracts or 
compounds to suppress sperm production and/or function. 
These approaches, which are noninvasive and aim to be 
reversible, are discussed in the following sections.
Immunocontraception: sperm proteins
Immunocontraception against various nonhormonal repro-
ductive targets has been investigated over the last decade. 
These targets include the successful zona pellucida targets 
used for animal castration in females (SpayVac™, SpayVac™ 
for Wildlife Inc, Princeton, NJ, USA).27,28 Sperm proteins 
are an attractive target as they are highly immunogenic, hav-
ing both auto- and isoantigens, are often specific to sperm, 
and thus do not affect other biological processes. Sperm 
proteins that have been investigated to date have been chosen 
especially for their sperm specificity, surface expression, 
involvement in fertility, and ability to raise high antibody 
titers that can neutralize fertility components. Antigens that 
are involved in human immune infertility are particularly 
attractive candidates. One of the first sperm proteins shown to 
induce specific serum immunoglobulin (Ig) G antibodies and 
IgA antibodies in vaginal fluids after administration to female 
Hypothalamus
GnRH
FSH LH
Pituitary 
gland
Sertoli
cells
Leydig 
cells
Testes
Spermatogenesis
T
T
+
+
+
GnRH-specific 
antibodies
Spermatozoa
Figure 1 Control of male fertility by immunization against gonadotropin-releasing 
hormone (GnRH). 
Notes: Vaccination  against  GnRH  produces  antibodies  that  act  by  neutralizing 
GnRH in the hypothalamus, which in turn affects secretion of follicle-stimulating 
hormone  (FSH),  luteinizing  hormone  (LH),  and  testosterone  (T)  and,  ultimately, 
spermatogenesis.
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mice was SP10.29 Some of the most researched sperm proteins 
are given in Table 2. As several reviews have provided detailed 
overviews of the research and status of anti-sperm contra-
ceptive vaccines and details of many of the sperm proteins 
investigated,30–32 these will not be addressed here.
The list of sperm proteins being investigated for immu-
nocontraception continues to grow and gene knockout 
technology has provided an invaluable tool for identify-
ing numerous sperm peptides that may have a role in 
sperm   function. However, many of these have only been 
investigated in the female for their ability to prevent 
sperm function within the female reproductive tract (eg, 
sperm–egg binding, capacitation). Few have been inves-
tigated for their ability to inhibit sperm function, such as 
motility, when administered to the male. This is primarily 
due to the incomplete understanding of male reproduc-
tive tract immunobiology and also to the large numbers 
of sperm that are required to be neutralized in the male 
epididymis and testis. The female reproductive tract poses 
fewer challenges to the successful inhibition of sperm 
function by an anti-sperm immunocontraceptive, due to 
the lower numbers of sperm presented in each ejaculate. 
Recent research has helped to move forward our under-
standing the immunological roles of both the testis and 
epididymis and the blood–testis barrier.33,34 This can only 
help facilitate the development of contraceptive vaccines 
for the male.
It also seems that the use of a single antigen in the devel-
opment of an anti-sperm vaccine may not provide a sufficient 
antibody response to reliably and consistently block fertility. 
Researchers are now looking at developing vaccines with 
more than one sperm protein in a single vaccine design.35 
In addition, new developments in vaccine technology, such 
as improved adjuvants36,37 and DNA vaccines,38 offer the 
potential to develop more effective and reliable contraceptive 
vaccines. Such vaccines have already shown efficacy when 
administered to male mice,39 thus may provide a way forward 
for reliable male immunocontraception.
Epididymal proteins
The epididymis is the site where sperm maturation occurs 
and is therefore a reasonable target for a male antifertility 
product. Spermatozoa become motile and are able to recog-
nize and fertilize an egg once they have progressed through 
the epididymis. As such, it is desirable to identify targets that 
interfere with this process and therefore be likely to inhibit 
sperm function. However, to date, attempts to interfere with 
either sperm maturation or epididymal function have not been 
successful.40 Some potential epididymal targets have been 
identified using transgenic animals but none has provided 
effective inhibition of sperm function.
The most promising target is proving to be the epididy-
mal protease inhibitor (EPPIN), a cysteine-rich protein that 
has antimicrobial properties and is thought to play a critical 
role in sperm motility. Eppin messenger RNA (mRNA) and 
the protein itself are found in abundance in both testis and 
epididymis of rats. Reverse-transcriptase polymerase chain 
reaction studies have demonstrated that the mRNA is also 
found in Sertoli and spermatogenic cells. Surgical castration 
downregulates EPPIN (mRNA and protein) expression levels 
in the caput and cauda epididymis, an effect that is reversed 
by testosterone replacement.41
During ejaculation, semenogelin (SEMG1) from seminal 
vesicles binds to EPPIN, initiating a series of events that 
includes the modulation of prostate-specific antigen (PSA) 
enzyme activity, provision of antimicrobial protection, 
causing inhibition of sperm motility.42 As PSA hydrolyses 
SEMG1, spermatozoa gain progressive motility. The immuni-
zation of male monkeys with recombinant EPPIN resulted in 
total, but reversible, contraception, demonstrating that it has a 
key role in male fertility.43   Currently, compounds that inhibit 
EPPIN function are being developed to provide additional 
information on its activities and whether it will become a 
suitable target for a prospective male contraceptive.44
In relation to the EPPIN studies, research has shown that 
the treatment of live spermatozoa with SEMG1 decreases the 
straight-line velocity and linearity of human spermatozoa.45 
This occurs in a dose- and time-dependent manner and 
subsequent treatment with PSA reverses the inhibition of 
progressive motility. Cysteine 239 of SEMG1 appears to be 
Table 2 Sperm proteins under investigation for contraceptive 
potential in males and females
Sperm protein Investigator/s Year
PH-20 Primakoff et al79 1988
SP10 Herr et al80 1990
ZRK Alexander81 1995
PH30 Vidaeus et al82 1997
SP17 Lea et al83 1998
CD52 Diekman et al84 2000
Acrosin Howes and Jones85 2002
SPAG9 Jagadish et al86 2006
SAGA-1 Xu et al87 2007
Izumo Wang et al88 2009
ESP Lv et al89 2010
CatSper Hildebrand et al90 2010
Proacrosin García et al39 2012
LDH-C4 Gupta91 2012
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critical for binding to EPPIN and inhibiting sperm motility.46 
SEMG1 may also have potential as a candidate target for 
male contraception.
Testicular kinases
Recently, there has been interest in testis-specific serine/
threonine kinases (TSSKs) as contraceptive targets and, as 
a result, focus on the development of small-molecule kinase 
inhibitors, which may inhibit fertility. These kinases and the 
substrates TSSK1–4, small serine/threonine kinase (SSTK), 
and  testis-specific serine kinase substrate (TSKS) are part of 
a family that is abundant in the testis and may provide tissue-
specific targets for contraceptive development.47 In rodents, 
in situ hybridization has confirmed that TSSK2, SSTK, and 
TSKS are post-meiotic in their expression patterns. This 
makes them possible targets for reversible contraceptive inter-
vention by preserving spermatogonia and spermatocytes. The 
current research may indicate that high-throughput screening 
of inhibitors for TSKS phosphorylation could provide targets 
for male contraception. However, this family of kinases is 
not strictly testis specific and may, therefore, not be suitable 
for human contraception.
Another group of kinases that has a role in spermato-
genesis is the tyrosine kinases, specifically the Src family 
and its subfamilies – for example, the Fes-related protein 
(Fer) subfamily. FerT (the truncated form) regulates actin 
assembly and disassembly, mediated by phosphorylation of 
cortactin. It is present in the “acroplaxome,” a cytoskeletal 
plate containing an F-actin network that links the acrosome 
to the spermatid nuclear envelope. This finding indicates that 
Fer kinase may represent one of the tyrosine protein kinases 
that contributes to spermatid headshaping.48
The specific roles of kinases in spermatogenesis and 
fertilization are a relatively new area of research and more 
information is required before it will be possible to evaluate if 
kinases will play a role in male contraceptive development.
Blood–testis boundary: epigenetic  
reader proteins (ERPs)
A new and interesting approach to male contraception has 
come from advances in the understanding of spermatogenesis 
at the molecular level. ERPs are involved in the chromatin 
remodelling of spermatogenesis, particularly bromodomain 
testis-specific protein (BRDT), a member of the bromodo-
main and extraterminal family of ERPs. “BRDT” is a 
tissue-restricted chromatin–associated protein located in 
pachytene and diplotene spermatocytes and spermatids.49 
It has recently been associated with both azoospermia and 
oligospermia in men.50 Interestingly, it has also been shown 
that suppression of BRDT function by a small-molecule, 
bromodomain inhibitor exerts a dose- and time-dependent 
inhibition on spermatogenesis in mice.51 Both human and 
mouse BRDT are highly conserved and seem to have nearly 
identical bromodomain pockets, indicating that the findings 
might be able to be translated to human males; this would 
potentially provide a novel and exciting approach for a small-
molecule-based male contraceptive.
Opioids
Opioids, which comprise part of the neuroendocrine system, 
are involved in the control of the male reproductive system 
on several levels. They are involved in the release of gonado-
tropins from the pituitary (Figure 2A); the function of Sertoli 
cells in the testis (Figure 2B); and the function and motility 
of spermatozoa (Figure 2C and D).52 The opioid system is 
controlled by endogenous opioid peptides (EOPs), which 
exert their action through opioid receptors for which the 
EOPs exhibit different affinities. Within the testis, the EOPs 
Hypothalamus
GnRH
FSH LH
Pituitary 
gland
ABP
ABP
Sertoli 
cells
Leydig 
cells
EOPs
Testes
Spermatogenesis
T
T
+
+
+
EOPs
LH
Motility
(+)
(−)
DOR
MOR
A
B
C
D
Figure  2  Control  of  male  fertility  using  the  opioid  system.  (A)  Control  of 
gonadotropin-releasing  hormone  (GnRH)  secretion,  which  in  turn  suppresses 
luteinizing hormone (LH) release; (B) control of opioid synthesis by LH in Leydig 
cells,  which  inhibits  Sertoli  cell  function  and  testosterone  levels  that  inhibit 
production  of  androgen-binding  protein  (ABP),  which  is  stimulated  by  follicle-
stimulating hormone (FSH) in Sertoli cells; (C) genetic control of opioid precursors 
that control spermatogenesis; and (D) further control of spermatozoa motility via 
receptors (mu-opioid receptor [MOR] and delta-opioid receptor [DOR]).
Abbreviations: EOPs, endogenous opioid peptides; T, testosterone.
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are present in different cell types and appear to intervene 
in the control of spermatogenesis. Opioid precursors are 
expressed differentially in testicular somatic and germ cells, 
suggesting that EOPs regulate testicular function locally by 
de novo synthesis. For example, LH stimulates production of 
EOPs in Leydig cells, and these suppress the role of Sertoli 
cells in a paracrine manner. However, the role of EOPs in 
germ-line sperm cells is still unknown. In addition, opioid 
receptors have been located on human sperm, which may 
indicate that EOPs directly affect sperm function, particularly 
sperm motility.53 With further research, EOPs may open up 
an area of novel contraceptive research and contribute to the 
development of novel nonhormonal male contraceptives.
Lonidamine derivatives: adjudin and gamendazole
Adjudin disrupts adhesion of spermatids to Sertoli cells and, 
in animals (male rats), weekly doses can induce total infertil-
ity 5 weeks after treatment.54 Similarly, another derivative, 
H2-gamendazole, has been shown to induce 100% infertility 
after just one dose in male rats, and it is possible that this 
compound will progress to clinical trial.55 However, it will 
need to show that it does not have long-term effects on the 
testis and that its contraceptive effect is reversible.
Retinoic acid (RA)
It is well established that the sperm production process, 
“spermatogenesis,” relies on the presence of vitamin A.56 
RA, the active metabolite of vitamin A, is required for sper-
matogonial differentiation and the production of sufficient 
numbers of sperm for fertilization.57 RA binds RA receptors 
that control gene expression.55 Certain compounds, such as 
bisdichloroacetyldiamines (eg, WIN 18446) have been shown 
to reversibly inhibit spermatogenesis by inhibiting testicular 
RA synthesis.58 However, to be a viable contraceptive, they 
also must not interfere with retinoic function or synthesis in 
non-testicular tissue. Currently, research is continuing on the 
development of novel inhibitors of retinoic synthesis that only 
affect spermatogenesis, but none are currently available.
Further, an RA receptor antagonist, BMS-189453, is also 
showing promise based on results in male rodents.59
MicroRNAs (miRNAs) and spermatogenesis
A new and exciting area of male reproductive research is 
the role of miRNAs in male fertility. The process of sper-
matogenesis is strictly regulated to enable and maintain the 
continuous production of spermatozoa. A novel mechanism 
of the post-transcriptional control of spermatogenesis, 
mediated by miRNAs, has recently been shown to be an 
important regulator of this process.60 miRNAs are endog-
enous, small, non-coding fragments produced through a 
multistep enzymatic process, which involves the action of 
Dicer (Dcr), an RNase III endonuclease.61 Dcr plays a key 
role in the biogenesis of miRNAs. To study RNA interference 
mechanisms in mammals, the first Dcr knockout mouse was 
generated by Bernstein et al.62 In their work, loss of Dcr led 
to early embryonic lethality and was characterized by almost 
total absence of embryonic stem cells, showing that Dcr is 
essential for murine embryonic development.62
Following on from these studies, the role of miRNAs 
in spermatogenesis63,64 and in Sertoli cell function65 was 
  investigated. It was found that spermatogenesis was disrupted 
if miRNAs were absent and the selective ablation of Dcr in 
Sertoli cells resulted in infertility, due to complete absence 
of spermatozoa. These experiments have opened up an 
intriguing aspect of testicular function and paracrine control. 
Although much more research needs to be undertaken on the 
role of miRNAs in spermatogenesis, such future work will 
increase our understanding of male fertility and possibly lead 
to new areas of male contraceptive research.
Plant extracts
Plants have been used for millennia for medicinal purposes, 
including in prevention of pregnancy and as abortifacient 
agents. Indeed, the first female oral contraceptive was derived 
from the roots of the Mexican wild yam.21 A recent review has 
examined the effects of different plant extracts on steroido-
genesis and spermatogenesis.66 The most widely researched 
plants to demonstrate nonhormonal antifertility effects are 
neem (Azadirachta indica) and gossypol, an extract of cotton-
seed oil. The latter has been studied in more than 8000 men 
and found to be very effective in producing azoospermia. 
However, it is very toxic and causes hypokalemia and irre-
versible infertility as a result of damage to the seminiferous 
epithelium.67,68 While many plant compounds have been 
researched, the quality control, safety, and mechanisms of 
action of plants have been less well studied. If this hurdle 
can be overcome, plants could offer a cost-effective source 
for male contraceptives, which could have relevance in low-
income countries.
Heat treatment
One method that does not fit into the chemical nonhormonal 
category is heat treatment. The use of local testicular heat 
treatment can cause reversible oligospermia or azoospermia 
via germ cell apoptosis.69 This method has recently been 
investigated as a possible male contraceptive. Liu70 showed 
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that single exposure of rat or monkey testes to a temperature 
of 43°C resulted in specific and reversible damage to the 
seminiferous epithelium. Local warming (30 minutes/day 
for 2 days) of monkey testes at 43°C showed that the sperm 
counts in the semen decreased by up to 80% at 28 days; 
further, this effect was reversible. In addition, when heat 
treatment was given in combination with a testosterone 
implant, the sperm count dropped to zero within 2 months. 
Withdrawal of the testosterone caused the count to recover 
to normal levels after 2–3 months. As such, this research has 
provided a theoretical, though perhaps impractical, basis for 
designing a combined male contraceptive.
Acceptability
For the past 50 years, researchers and family planning organi-
zations have focused on female methods of contraception in 
the belief that women bear most of the health and economic 
impact of childbearing and child raising. However, since the 
mid-1990s, there has been a change in attitude and it is now 
recognized that contraceptives should be developed for both 
men and women.
The acceptability of male contraception can be mea-
sured by the prevalence and continuation of use of a par-
ticular method. Men are mostly involved in decisions of 
pregnancy prevention methods when part of a married or 
in-union couple and male contraceptive methods account 
for about 26% of the global contraceptive prevalence.71 
Historically, the male methods of withdrawal and periodic 
abstinence have been the only contraceptive methods used 
and accepted by men72 and although these methods are still 
currently in use by almost 35 million couples around the 
world, it appears that prevalence is dependent on cultural, 
religious, economic, and relationship status. These meth-
ods comprise only 6.6% of the contraceptives used in the 
world today.73
Condoms and vasectomy are so-called modern methods 
of contraception that are accessible to men. While use of 
condoms has increased, vasectomy has decreased in some 
countries due to the advent of female sterilization.74 Differ-
ences can be seen between regions of the world, with 17.8% of 
male condom use occurring in more developed regions com-
pared with 6.9% in less developed regions.73 There are also 
variations in prevalence of male condom use within regions. 
For example, considering more developed regions, male 
condom use in Hong Kong and Japan, accounts for 50% and 
40%, respectively, of all the contraceptive measures used in 
these countries, while it accounts for only 1.1% in Germany. 
Similarly, the percentage of use in less developed regions 
varies from 15.5% in Botswana to 0.2% in Samoa.73
Worldwide, vasectomy accounts for about 2.4% of all 
used male contraception methods. It is most preferred in more 
developed countries and educated communities; for example, 
more than 20% of men in Canada and the UK choose it for 
preventing pregnancy. However, again, prevalence varies across 
regions; in Germany, for example, this method accounts for 
only 0.5% of all contraceptive methods used. Prevalence is 
much lower in less developed countries, with almost no men in 
African countries, for example, opting for surgical sterility.
All reported acceptability data have been based on trial 
surveys carried out among young men and their partners. 
A male pill or injection has been reported to be considered very 
acceptable by both men and women, as it may increase choice 
of reversible sterility methods.6 Further, more than three-
quarters of men who participated in hormonal   contraception 
clinical trials from six different cultural settings reported their 
intention to definitely or probably use such methods in the 
future when available.75 In another study, men and women were 
interviewed in Edinburgh, Shanghai, Hong Kong, and Cape 
Town and between 44% and 88% of men stated that they would 
use a daily contraceptive pill. In contrast, most women (70% 
[from Hong Kong] to .90% [Cape Town and Edinburgh]) 
thought it was a good idea and only 2% said that they would 
not trust their partners to take the male pill.75 A wider survey 
in nine countries over four continents consisting of 9000 men 
aged 18 to 50 years indicated that .55% would accept use 
of a male contraceptive method and that the most preferred 
method was a daily oral pill, the second most preferred method 
was monthly injection, then yearly implant.76 Studies have also 
shown that although men have an increasing knowledge of the 
male contraceptive choices available to them, they may not 
use these methods.77 Education, cultural and religious beliefs 
remain hurdles to acceptability.
Future prospects
From the overview of methods in development provided, 
the most promising new method appears to be RISUG as 
an alternative to vasectomy. However, this method may 
not be widely accepted (given the current prevalence of 
vasectomy for contraceptive purposes) and require special-
ist application. In the short-term, the likeliest method to be 
made readily available and be widely accepted would be a 
hormonal contraceptive pill. However, without commitment 
to a daily regime, this method would prove ineffective if 
compliance were compromised. Long-term, research into 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
8
Garside et alOpen Access Journal of Contraception 2013:4
suitable targets for immunocontraception may well provide a 
source for new-generation male contraceptive products such 
as those administered via mucosal vaccination. Vaccination 
removes the need for a daily regime, while the mucosal route 
potentially allows for self-administration.
Conclusion
In the near future, the choice of male contraceptive meth-
ods may increase. However, the availability of more male 
contraceptive methods is insufficient by itself. There is 
also an urgent requirement for governments and non-
government organizations to break the gender imbalance 
concerning contraceptive usage that exists globally, and 
which continues to be an obstacle to effective population 
control. The introduction of hormonal contraception for 
women was seen as revolutionary in that it empowered 
women and provided them with the opportunity to control 
their fertility. However, the success of female hormonal 
contraception, particularly in the developed world, has in 
many ways been detrimental and has perpetuated the view 
that contraceptive responsibility and its associated health 
and financial burdens remain with women. Although this 
has been considered to provide women empowerment and 
equality, which may no doubt be true, it has until recently 
stifled innovation in male contraception, with the focus of 
continued contraceptive development and adoption placed 
on females. Perhaps it is time for males to accept that male 
reproductive autonomy could also be empowering for them 
as it has been for women and is a valid price to pay for 
sexual liberalization. More widely, it also provides males 
with the opportunity to jointly accept and contribute to 
population control.
With regard to the commercial production of novel male 
contraceptives, the current consolidation of pharmaceutical 
companies has reduced competition and this has been com-
pounded by the loss of profitability of many contraceptives 
due to short-lasting patents. Health care reforms – such as 
those in the USA – may also further discourage new product 
development. However, the creation of new contraceptives 
may still be possible through the efforts of small start-up 
companies, philanthropic foundations, and governmental 
research enterprises.
Progress is being made in terms of new hormonal and 
nonhormonal drug targets, as evidenced by the increase in pub-
lished studies, even in the last year. While the global economy 
is in recession, there is an even greater need for increasing the 
availability of cost-effective and safe contraceptive options.
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